# A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer

Source: https://onco.cc/trials/nct07051486/  
OnCo record `nct07051486` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Trastuzumab rezetecan in cervical cancer, run by Jiangsu HengRui Medicine Co., Ltd., now recruiting.

## Summary

A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer is a phase 2 interventional study registered as NCT07051486 by Jiangsu HengRui Medicine Co., Ltd., with 60 participants planned, started 2025-10-11 and due to reach its primary completion in 2026-02. Interventions recorded: SHR-A1811 Injection. Conditions listed: Recurrent or Metastatic Cervical Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07051486
- Phase: 2
- Setting: A Single-Arm, Multicenter Phase II Clinical Trial of SHR-A1811 for Injection in Patients With HER2-Expressing Recurrent or Metastatic Cervical Cancer Progressing After Standard Treatment
- Sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT07051486: https://clinicaltrials.gov/study/NCT07051486

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/)
- drugs: [Trastuzumab rezetecan](https://onco.cc/drugs/trastuzumab-rezetecan/)
- companies: [Jiangsu Hengrui Pharmaceuticals](https://onco.cc/companies/hengrui/)

---
JSON: https://onco.cc/api/v1/entities/nct07051486.json